KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

Abstract excerpt

PURPOSE: Activating mutation of the KRAS oncogene is an established predictive biomarker for resistance to anti-epidermal growth factor receptor (anti-EGFR) therapies in advanced colorectal cancer (aCRC). We wanted to determine whether KRAS and/or BRAF mutation is also a predictive biomarker for other aCRC therapies. PATIENTS AND METHODS: The Medical Research Council Fluorouracil, Oxaliplatin and Irinotecan: Use...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Camptothecin
• Share to Fluorouracil